Good manufacturing practice: how a GMP regime rewires a factory's decision rights

The batch record becomes the product

Under this regime the physical goods and their documentation are inseparable: material that meets specification but whose record is incomplete cannot be treated as good product. Everything a batch experienced is captured contemporaneously — weights, equipment identity, operators, environmental conditions, in-process results, deviations and their outcome. That imposes a rhythm operators sometimes resent, because recording happens as work happens rather than at the end of a shift. It also gives the site something rare: a genuine ability to reconstruct what happened when a complaint arrives long after the people involved have moved on.

Validation freezes the process you eventually want to improve

Once a process, cleaning method, analytical test or computerised system has been qualified, changing it is a project rather than an adjustment. That is the point, and it is also the cost. A production engineer who would elsewhere retune a parameter on a Tuesday afternoon here raises a change, assesses impact on product quality, gathers data, updates documents, retrains and possibly informs a regulator. Sites that treat this as bureaucracy accumulate undocumented drift and eventually fail an inspection; sites that plan improvement in defined waves rather than continuously make progress without breaking the qualified state.

Supplier and material changes are quality decisions

Switching an excipient supplier, a filter, a container closure or a contract laboratory is not a purchasing matter that quality is told about afterwards. Materials are qualified, suppliers are approved on defined grounds, and a substitution can require testing, stability data or a regulatory submission before it is usable. This is where commercial and quality functions collide hardest, because procurement is measured on cost and continuity while the qualified source is fixed. The practical consequence is that dual sourcing in this sector has a lead time measured in programme terms rather than in negotiation terms.

Deviations, investigations and the temptation to normalise

Every departure from the approved method has to be recorded and assessed for product impact, which produces a steady stream of investigations. The failure mode is not too many deviations but repeated ones closed with the same shallow cause and no effective action, which inspectors read as a quality system that observes problems without fixing them. Trending matters as much as individual closure: a recurring environmental excursion or a repeated equipment fault tells a story about maintenance and facility condition that the individual records never do. Reviewing deviation trends alongside the maintenance backlog usually explains more than either record does alone.

Inspection and where the operative expectations are published

Medicines authorities inspect sites, examine records, interview staff and can restrict supply or approval where they find serious problems. Their published guidance, inspection observations and question-and-answer material are the primary sources on expectations, and they differ between territories even where mutual recognition arrangements exist. What follows from that for your site — which requirements bite, which product classes are covered, what a change obliges you to notify — is a matter for those regulators and for regulatory affairs professionals rather than for a general overview like this. Reading recent published inspection findings from those authorities is among the least expensive preparation available.

Frequently asked questions

How is GMP different from an ISO 9001 quality system?

A general quality management system asks you to define your processes and show they work as defined, leaving the standard of the process largely to you. A GMP regime specifies expectations for premises, equipment, documentation, personnel, release and record retention, and is enforced by a public authority with powers over your ability to sell. Many sites run both, using the management system for business processes and GMP for product-affecting activity, but one does not substitute for the other.

Can we run GMP and non-GMP production in the same building?

Sites do, but it needs deliberate design around segregation, air handling, material and personnel flows, cleaning between campaigns and clear equipment status control, and certain product types are treated as unsuitable for shared facilities altogether. The determination is product-specific and rests on contamination risk, so it belongs with your regulatory adviser and the inspecting authority. Retrofitting segregation after a shared arrangement has been running is considerably harder than designing it in.

Who is allowed to release a batch for sale?

A designated individual with defined responsibility and appropriate qualifications, whose independence from production pressure is part of the point. The title, qualifications and legal duties attached to the role differ between jurisdictions, so the same function is not interchangeable across borders. What is consistent is that release is a personal decision made against the complete record, and that it cannot be delegated to someone whose objective is shipping the order on time.